Instigators of COVID-19 in Immune Cells Are Increased in Tobacco Cigarette Smokers and Electronic Cigarette Vapers Compared With Nonsmokers

Theodoros Kelesidis MD PhD¹, Yuyan Zhang BS¹, Elizabeth Tran BS², Grace Sosa¹, Holly R. Middlekauff MD²•

¹Department of Medicine, Division of Infectious Disease, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; ²Department of Medicine, Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Corresponding Author: Holly R. Middlekauff, MD, Department of Medicine, Division of Cardiology, David Geffen School of Medicine at UCLA, A2-237 CHS, 650 Charles Young Drive South, Los Angeles, CA 90025, USA. Telephone: 310-206-6672; Fax: 310-206-9133; E-mail: hmiddlekauff@mednet.ucla.edu

Abstract

Introduction: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for the COVID-19 pandemic, gains entry into the host cell when its Spike protein is cleaved by host proteases TMPRSS2 and furin, thereby markedly increasing viral affinity for its receptor, angiotensin-converting enzyme-2 (ACE2). In rodent and diseased human lungs, tobacco cigarette (TCIG) smoke increases ACE2, but the effect of electronic cigarette vaping (ECIG) is unknown. It is unknown whether nicotine (in both TCIGs and ECIGs) or non-nicotine constituents unique to TCIG smoke increase expression of key proteins in COVID-19 pathogenesis.

Methods: Immune (CD45+) cells collected before the pandemic in otherwise healthy young people, including TCIG smokers (n = 9), ECIG vapers (n = 12), or nonsmokers (NS) (n = 12), were studied. Using flow cytometry, expression of key proteins in COVID-19 pathogenesis were compared among these groups.

Results: TCIG smokers and ECIG vapers had similar smoking or vaping burdens as indicated by similar plasma cotinine levels. TCIG smokers compared with NS had a significantly increased percentage of cells that were positive for ACE2 (10-fold, p < .001), TMPRSS2 (5-fold, p < .001), and ADAM17 (2.5-fold, p < .001). Additionally, the mean fluorescence intensity (MFI) consistently showed greater mean ACE2 (2.2-fold, p < .001), TMPRSS2 (1.5-fold, p < .001), furin (1.1-fold, p < .05), and ADAM17 (2-fold, p < .001) in TCIG smokers compared with NS. In ECIG vapers, furin MFI was increased (1.15-fold, p < .05) and TMPRSS2 MFI tended to be increased (1.1-fold, p = .077) compared with NS.

Conclusions: The finding that key instigators of COVID-19 infection are lower in ECIG vapers compared with TCIG smokers is intriguing and warrants additional investigation to determine if switching to ECIGs is an effective harm reduction strategy. However, the trend toward increased proteases in ECIG vapers remains concerning.

Implications: (1) This is the first human study to report a marked increase in proteins critical for COVID-19 infection, including ACE2, TMPRSS2, and ADAM17, in immune cells from healthy tobacco cigarette smokers without lung disease compared with e-cigarette vapers.
Introduction

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for COVID-19, has infected almost 180 million people worldwide, resulting in almost 4 million deaths in the ongoing COVID-19 pandemic. SARS-CoV-2 gains cell entry when its spike protein binds to the host receptor, angiotensin-converting enzyme-2 (ACE2). Before the spike protein can bind to its receptor, it is cleaved or “primed” by host proteases such as TMPRSS2 and furin, thereby increasing affinity for the host receptor ACE2 by 20-fold. Beyond this, very little is known about mechanisms of virulence of the SARS-CoV-2 and the factors increasing vulnerability to severe infection. The role of smoking has been controversial. Paradoxically, unlike virtually any other respiratory infection, tobacco cigarette (TCIG) smokers have been underrepresented in reports of patients hospitalized with COVID-19. This has led to speculation that something in TCIG smoke, specifically nicotine which has anti-inflammatory effects, is protective. On the other hand, TCIG smoking has been identified as a risk factor for progression to more severe disease and death in those already hospitalized with COVID-19.

ACE2, the receptor for SARS-CoV-2, is ubiquitous in human tissues, present in the lung, gut, kidney, heart, and other tissues, as well as in endothelial, vascular smooth muscle, and immune cells. This ubiquity may explain, in part, the diverse presentations of COVID-19, including the cytokine release syndrome that is responsible for many deaths. Importantly, in rodent and diseased human lungs, TCIG smoking is associated with increased ACE2 expression. It is unknown if increased ACE2 is attributable to the underlying TCIG-associated lung disease or if TCIG smoke itself increases ACE2 expression, even in the absence of lung disease. Electronic cigarette (ECIG) vaping is increasing among smokers trying to quit, but also among young nonsmokers. Emissions from ECIGs contain far fewer toxins, which, if detected at all, are present in concentrations orders of magnitude lower compared with emissions from TCIGs—except for one, nicotine. Levels of cotinine, the metabolite of nicotine, are comparable in smokers and vapers. ECIG vaping has variably been associated with increased risk, and no increased risk, for COVID-19 diagnosis.

We reasoned that studies in healthy young people without lung disease, who only smoke TCIGs or only vape ECIGs, would clarify this issue whether TCIG smoking alone, in the absence of lung disease, increases expression of key instigators of COVID-19 infection, such as ACE2 and several proteases. Moreover, these findings would provide insights into the relative effects of TCIG smoking and ECIG vaping, thereby providing valuable and urgently needed information to inform public health strategies to decrease vulnerability to COVID-19 infection.

Methods

The data that support the findings of this study are available from the corresponding author on reasonable request. Accessible peripheral blood mononuclear cells (PBMCs) collected in 2019, before the pandemic, from 33 (19 males) healthy young (mean age of 24 years old) people, including 9 chronic TCIG smokers, 12 chronic ECIG vapers, and 12 nonsmokers, were available for study. Baseline characteristics of participants including age, sex, race, and educational level have been published and did not differ among groups. Seven of the 12 ECIG vapers were former TCIG smokers, all quitting more than 2 years before the study. None were current TCIG smokers. Importantly, TCIG smokers and ECIG vapers had similar current smoking and vaping burdens based on plasma cotinine levels, and all had refrained from smoking 12 hours before the study session.

To confirm whether the expression of these key proteins in accessible PBMCs has relevance to other target tissues for the SARS-CoV-2 virus, expression of ACE2, TMPRSS2, furin, or ADAM17 in gut tissue, a target tissue for SARS-CoV-2 infection that has the same embryogenesis as lung tissue, was correlated with PBMC expression. Gut epithelial tissue was available from colonoscopies performed in 11 otherwise healthy nonsmokers (10 males, mean age 52 years).

This is an exploratory, hypothesis-generating small study, and we did not adjust for multiple comparisons. The experimental protocols were approved by the Institutional Review Board, and all participants provided written informed consent.

Results

Percentage of Immune (CD45+) Cells Positive for Key Proteins in COVID-19 Infection

TCIG smokers had a strikingly increased percentage of CD45+ immune cells that were positive for ACE2, TMPRSS2, and ADAM17 compared with ECIG vapers and nonsmokers (Supplementary Figure 1A–H). In contrast, the percentage of immune cells that were positive for ACE2, TMPRSS2, and ADAM17 in ECIG vapers and nonsmokers were virtually identical. The percentage of CD45+ cells positive for furin was not different among the three groups.

Mean Fluorescence Intensity of Key Proteins in COVID-19 Infection

Between group comparisons of the mean fluorescence intensity (MFI) consistently demonstrated greater ACE2, TMPRSS2, and ADAM17 levels in CD45+ cells from TCIG smokers compared with ECIG vapers and nonsmokers (Supplementary Figure 1I–D). Furin MFI in CD45+ cells from TCIG smokers was also higher compared with nonsmokers (Supplementary Figure 1K and L). In CD45+ cells from ECIG vapers, furin MFI was increased, whereas TMPRSS2 MFI tended (p = .077) to be increased compared with nonsmokers (Supplementary Figure 1J).

Expression of each these key proteins in gut cells was positively and consistently correlated with respective protein levels in PBMCs (Supplementary Figure 2A–F).
Discussion
To the best of our knowledge, this is the first human study to report a marked increase in ACE2, TMPRSS2, and ADAM17 in TCIG smokers compared with ECIG vapers and nonsmokers. The increases in key instigators of COVID-19, including ACE2, in otherwise healthy young TCIG smokers in the absence of clinical lung disease demonstrates that TCIG smoking itself induces upregulation of these proteins. Importantly, this increase in ACE2 and proteases levels was not induced by a differences in the burden of TCIG smoking and ECIG vaping, since plasma cotinine levels were not different, implicating non-nicotine toxicants in TCIG smoke in inducing expression of ACE2 and proteases. Although this increased expression may be reversible, since many of our ECIG vapers were former TCIG smokers, this remains speculative. Furthermore, ECIG vapers had a small increase in TMPRSS2 and furin in immune cells compared with nonsmokers, a finding that deserves further study.

Although the role of TCIG smoking in SARS-CoV-2 infection remains controversial, our study contributes to the evidence that smoking is harmful. Importantly, in TCIG smokers, the upregulation of (1) ACE2, the receptor for SARS-CoV-2; (2) TMPRSS2 and furin, which modify the spike protein enhancing affinity 20-fold for ACE2; and (3) ADAM17, which may worsen lung injury in COVID-19 by promoting inflammation through ACE2 shedding and dysregulation of IL-6, a correlate of mortality in COVID-19, provides insight into the mechanisms whereby TCIG smoking may increase vulnerability to severe COVID-19, even in healthy young smokers.

Our study is a small study. Nonetheless, using two different and complementary measures, we were able to find a consistent increase in cellular ACE2, TMPRSS2, and ADAM17 in TCIG smokers compared with nonsmokers. We studied readily accessible PBMCs instead of more commonly infected, but comparatively inaccessible, cells such as lung epithelial cells. We reasoned that PBMCs were reasonable surrogates since we found that expression of these key proteins in PBMCs was positively correlated with respective protein levels in gut cells, and gut and lung tissue have the same embryogenesis. Nonetheless, confirmation of these findings in additional participants and tissues is warranted.

In conclusion, the finding that key instigators of COVID-19 in immune cells are lower in chronic ECIG vapers compared with TCIG smokers is intriguing and warrants additional investigation to determine whether switching to ECIGs may be a harm-reduction strategy. However, the trend toward increased proteases in ECIG vapers remains concerning.

Supplementary Material
A Contributorship Form detailing each author’s specific involvement with this content, as well as any supplementary data, are available online at https://academic.oup.com/ntr.

Funding
This work was supported by the Tobacco-Related Disease Research Program (TRDRP) under the contract number TRDRP 28IR-0065 (HRM), by University of California Office of the President under the contract number R00IRG27479 Emergency COVID-19 Research Seed Funding (HRM), and by the National Institute of Health National Center for Advancing Translational Science (NCATS) University of California, Los Angeles Clinical and Translational Science Institute (grant number LIRTR001881). This work was also supported in part by NIH grants R01AG059501, R03AG059462 (to TK). The flow cytometry machine used in the study was purchased through the UCLA Center for AIDS Research (P30AI28697) grant.

Declaration of Interests
None declared.

References
1. World Health Organization. Coronavirus (COVID-19) Dashboard. https://covid19.who.int. Accessed June 26, 2021.
2. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS-coronavirus-induced lung injury. Nat Med. 2005;11(8):875–879.
3. Lippi G, Lavie CJ, Henry BM, Sanchis-Gomar F. Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)? Clin Chem Lab Med. 2020;58(9):1415–1422.
4. Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction. 2021;116(6):1319–1368.
5. Farsalinos K, Niaura R, Le Houezec J, et al. Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotine cholinergic system. Toxicol Rep. 2020;8:73–83. doi:10.1016/j.toxrep.2020.12.013. ecollection 2021; PMID: 33425684.
6. Umuyuwanire A, Kanchanasurakit S, Lucero-Prisno DEI, Saokaew S. Smoking and risk of negative outcomes among COVID-19 patients: a systematic review and meta-analysis. Tob Induc Dis. 2021;19:09.
7. Smith JC, Sausville EL, Geish V, et al. Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract. Dev Cell. 2020;53(5):314–329.e3.
8. Mayer M, Reyes-Guzman C, Grana R, Choi K, Freedman ND. Demographic characteristics, cigarette smoking, and e-cigarette use among US adults, JAMA Netw. Open. 2020;3(10):e2026094.
9. Wang TW, Neff LJ, Park-Lee E, Ren C, Cullen KA, King BA. E-cigarette use among middle and high school students – United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(37):1310–1312.
10. Shahab L, Goniewicz ML, Blount BC, et al. Nicotine, carcinogen, and toxicity analysis in long-term e-cigarette and nicotine replacement therapy users: a cross-sectional study. Ann Intern Med. 2017;166(6):400–409.
11. Gaiba SM, Cheng J, Halpern-Felsher B. Association between youth smoking, electronic cigarette use, and COVID-19. J Adolesc Health. 2020;67(4):519–523.
12. Jose T, Croghan IT, Hays JT, Schroeder DR, Warner DO. Electronic cigarette use is not associated with COVID-19 diagnosis. J Prim Care Community Health. 2021;12:2150317211024391.
13. Kelesidis T, Tran E, Arastoo S, et al. Elevated cellular oxidative stress in circulating immune cells in otherwise healthy young people who use electronic cigarettes in a cross-sectional single-center study: Implications for future cardiovascular risk. J Am Heart Assoc. 2020;9(18):e016983.
14. Gustafson MP, Lin Y, Maas ML, et al. A method for identification and analysis of non-overlapping myeloid immunophenotypes in humans. PLoS One. 2015;10(3):e0121546.
15. Lambert DW, Yarski M, Warner DO, et al. Tumor necrosis factor-alpha convertase(ADAM17) mediates regulated ectodomain shedding of the severe acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem. 2005;280(34):30113–30119.
16. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848. doi:10.1007/s00134-020-05991-x. PMID: 32125452.
17. Faure S, de Santa Barbara P. Molecular embryology of the foregut. J Pediatr Gastroenterol Nutr. 2011;52(suppl 1):S2–S3.
18. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263.
19. Fairchild A, Healton C, Curran J, Abrams D, Bayer R. Evidence, alarm, and the debate over e-cigarettes. Science. 2019;366(6471):1318–1320.